152 filings
Page 6 of 8
8-K
9v7k 7u96il
3 Aug 17
Revance Releases Second Quarter 2017 Results
12:00am
8-K
dsq5w
2 Aug 17
Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics
12:00am
8-K
fda4lzs jlbmbl1
6 Jun 17
Regulation FD Disclosure
12:00am
8-K
cdbm34580v406pc
5 Jun 17
Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial
12:00am
8-K
j2twp9qg
18 May 17
Regulation FD Disclosure
12:00am
8-K
daf9bi6
12 May 17
Departure of Directors or Certain Officers
12:00am
8-K
l7t0if7ndn xbj
9 May 17
Revance Therapeutics 1Q 2017 Conference Call
12:00am
8-K
smuq5u5b2xjjtz rvx4
9 May 17
Revance Releases First Quarter 2017 Results
12:00am
8-K
5rq9dk n1grjb7
15 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
58meas8owhd3bb
27 Feb 17
Revance Releases Fourth Quarter and Full Year 2016 Results
12:00am
8-K
0cy36kfy
1 Feb 17
Departure of Directors or Certain Officers
12:00am
8-K
4oyf0sodjjru1s8bsg
12 Jan 17
Other Events
12:00am
8-K
wfjvel4x
5 Jan 17
Revance Provides Clinical Milestones and Financial Outlook for 2017
12:00am
8-K
nzgqpon q396gm72u
12 Dec 16
Regulation FD Disclosure
12:00am
8-K
6umahz8 b8v
3 Nov 16
Revance Releases Third Quarter 2016 Results
12:00am
8-K
44q2 ku7i1r
4 Aug 16
Revance Releases Second Quarter 2016 Results
12:00am
8-K
5uc bgb1jiwie9fv
5 Jul 16
Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors
12:00am
8-K
dllbynd3
13 Jun 16
Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
12:00am
8-K
t1ndqgbvmvk
3 Jun 16
Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio
12:00am
8-K
q6w34um
9 May 16
Revance Releases First Quarter 2016 Results
12:00am